InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | 2026-05-20 | Charles Faith L. | Director | Purchase | 7,100 | $4.79 | $34K | 7,100 | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| General and administrative | $6.2M+10.7% | $5.6M+17.7% | $4.8M-20.1% | $6.0M |
| Research and development | $9.8M+5.2% | $9.3M-34.1% | $14.1M+51.6% | $9.3M |
| Total operating expenses | $16.0M+7.3% | $14.9M-21.0% | $18.9M+23.6% | $15.3M |
| Loss from operations | -$16.0M-7.3% | -$14.9M+21.0% | -$18.9M-23.6% | -$15.3M |
| Other expense | -$3K | $0 | — | — |
| Interest income | $154K+155.2% | $60K+117.7% | $28K | $0 |
| Interest expense | -$15K+5.5% | -$16K-16.8% | -$14K-96.5% | -$7K |
| Total other income (expense) | $136K+208.1% | $44K+218.0% | $14K+297.6% | -$7K |
| Net loss | -$15.9M-6.7% | -$14.9M+21.2% | -$18.9M-23.4% | -$15.3M |
| Loss per share - basic | -$35.75+92.3% | -$466.89+96.3% | -$13K-111389.4% | -$11.22 |
| Loss per share - diluted | -$35.75+92.3% | -$466.89+96.3% | -$13K-111389.4% | -$11.22 |
| Weighted average shares outstanding - basic | $443K+1293.2% | $32K+2011.7% | $2K-99.9% | $1.4M |
| Weighted average shares outstanding - diluted | $443K+1293.2% | $32K+2011.7% | $2K-99.9% | $1.4M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
Top Midday Gainers